Katie Pike on Muck Rack

Katie Pike

United Kingdom
As seen in: Homes & Antiques, BMJ Open, heart, Journal of Infection
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Katie

Contact Katie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial

|
By Rosie Harris, Claire McBrien, Russell Thirard, David Chadwick, John Jackson, Ed Moran, James Perry, Ruth Payne, Anna Goodman, Catherine A Cosgrove, Stevan R. Emmett, Adam Finn, Katie Pike, Lucy A Culliford, Rajeka Lazarus, Russell Thirard, Alexander Middleditch, Patrick Lille
| Journal of Infection Verified
Keywords Recombinant shingles vaccine adjuvanted influenza vaccine mRNA COVID-19 vaccine co-administration concomitant vaccination Introduction The global population is ageing. In England, 19% of the adult population is estimated to be aged 65 and over and this number is set to increase to 26% over the next 40 years.1 The increase in chronic medical conditions and a decline in immunity associated with ageing leads to an increased susceptibility to infection.
Open in Who Shared Issue with article?

Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness-a protocol for a randomised controlled trial (ASTUTE trial) | BMJ Open

|
By Barnaby C. Reeves, chris rogers, Katie Pike, Lucy A Culliford
| BMJ Open Verified
Methods and analysis The ASTUTE trial is a multicentre, parallel-group, placebo-controlled, pragmatic RCT with a treatment run-in (TRI). In the TRI, eligible participants will receive open-label adalimumab for 16 weeks. At 16 weeks, participants will be assessed, and only those classified as having a therapeutic response will be randomised. The study schema is shown in figure 1. The target population is adults with active or controlled ANIU.
Open in Who Shared Issue with article?

"Gone" by Katie Pike

|
By Katie Pike
| scholarsarchive.byu.edu
Home > INSCAPE > Vol. 34 (2014) > No. 1 Recommended Citation Pike, Katie (2014) "Gone," Inscape: Vol. 34 : No. 1 , Article 13. Available at: https://scholarsarchive.byu.edu/inscape/vol34/iss1/13 DOWNLOADS Since June 22, 2019 COinS
Open in Who Shared Issue with article?
See all 5 licensed articles (52 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified